Trial Outcomes & Findings for Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension (NCT NCT02867813)

NCT ID: NCT02867813

Last Updated: 2023-04-07

Results Overview

All adverse event summaries for the primary analysis of the primary endpoint (OLE study period only) included all treatment-emergent events reported on the Event electronic case report form (eCRF), including CEC positively reviewed events and disease-related events.

• Recruitment status: COMPLETED
• Study phase: PHASE3
• Target enrollment: 5035 participants
• Primary outcome timeframe: Up to 5 years
• Results posted on: 2023-04-07

Participant Flow

This was an open-label extension of study 20110118 (NCT01764633). Eligible participants were enrolled after the completion of the 20110118 study. 5035 participants were enrolled at 195 centers in Czech Republic, Hungary, Poland, Russia, Slovakia, Ukraine, and the United States from 02 September 2016 to 17 March 2022.

5035 participants were enrolled and 5031 of those participants received study drug.

Participant milestones

Measure	Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study Participants in the parent study who received placebo subcutaneous injections either Q2W or QM, and received evolocumab 140 mg every 2 weeks Q2W or 420 mg monthly QM in the open label extension, according to the participant's preference.	Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study Participants in the parent study who received evolocumab subcutaneous injections either Q2W or QM, and received evolocumab 140 mg Q2W or 420 mg QM in the open label extension according to the participant's preference.
Overall Study STARTED	2535	2500
Overall Study COMPLETED	2084	2090
Overall Study NOT COMPLETED	451	410

Reasons for withdrawal

Measure	Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study Participants in the parent study who received placebo subcutaneous injections either Q2W or QM, and received evolocumab 140 mg every 2 weeks Q2W or 420 mg monthly QM in the open label extension, according to the participant's preference.	Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study Participants in the parent study who received evolocumab subcutaneous injections either Q2W or QM, and received evolocumab 140 mg Q2W or 420 mg QM in the open label extension according to the participant's preference.
Overall Study Withdrawal by Subject	57	56
Overall Study Decision by Sponsor	7	7
Overall Study Lost to Follow-up	91	78
Overall Study Missing	2	1
Overall Study Death	294	268

Baseline Characteristics

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

Baseline characteristics by cohort

Measure	Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study n=2532 Participants Participants in the parent study who received placebo subcutaneous injections either Q2W or QM, and received evolocumab 140 mg every 2 weeks Q2W or 420 mg monthly QM in the open label extension, according to the participant's preference.	Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study n=2499 Participants Participants in the parent study who received evolocumab subcutaneous injections either Q2W or QM, and received evolocumab 140 mg Q2W or 420 mg QM in the open label extension according to the participant's preference.	Total n=5031 Participants Total of all reporting groups
Age, Continuous	62.3 Years STANDARD_DEVIATION 8.4 • n=5 Participants	62.4 Years STANDARD_DEVIATION 8.5 • n=7 Participants	62.3 Years STANDARD_DEVIATION 8.4 • n=5 Participants
Sex: Female, Male Female	638 Participants n=5 Participants	622 Participants n=7 Participants	1260 Participants n=5 Participants
Sex: Female, Male Male	1894 Participants n=5 Participants	1877 Participants n=7 Participants	3771 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	55 Participants n=5 Participants	63 Participants n=7 Participants	118 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	2477 Participants n=5 Participants	2436 Participants n=7 Participants	4913 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	5 Participants n=5 Participants	2 Participants n=7 Participants	7 Participants n=5 Participants
Race/Ethnicity, Customized Asian	9 Participants n=5 Participants	21 Participants n=7 Participants	30 Participants n=5 Participants
Race/Ethnicity, Customized Black or African American	111 Participants n=5 Participants	117 Participants n=7 Participants	228 Participants n=5 Participants
Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander	5 Participants n=5 Participants	4 Participants n=7 Participants	9 Participants n=5 Participants
Race/Ethnicity, Customized White	2392 Participants n=5 Participants	2345 Participants n=7 Participants	4737 Participants n=5 Participants
Race/Ethnicity, Customized Multiple	4 Participants n=5 Participants	4 Participants n=7 Participants	8 Participants n=5 Participants
Race/Ethnicity, Customized Other	6 Participants n=5 Participants	6 Participants n=7 Participants	12 Participants n=5 Participants

PRIMARY outcome

Timeframe: Up to 5 years

Population: OLE Safety Analysis Set which included all participants who received at least 1 dose of open-label evolocumab in the OLE study.

All adverse event summaries for the primary analysis of the primary endpoint (OLE study period only) included all treatment-emergent events reported on the Event electronic case report form (eCRF), including CEC positively reviewed events and disease-related events.

Outcome measures

Measure	Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study n=2532 Participants Participants in the parent study who received placebo subcutaneous injections either Q2W or QM, and received evolocumab 140 mg every 2 weeks Q2W or 420 mg monthly QM in the open label extension, according to the participant's preference.	Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study n=2499 Participants Participants in the parent study who received evolocumab subcutaneous injections either Q2W or QM, and received evolocumab 140 mg Q2W or 420 mg QM in the open label extension according to the participant's preference.
Number of Participants Who Experienced an Adverse Event	2144 Participants	2084 Participants

SECONDARY outcome

Timeframe: Week 12, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 168, Week 192, Week 216, Week 260

Population: OLE Safety Analysis Set which included all participants who received at least 1 dose of open-label evolocumab in the OLE study.

Outcome measures

Measure	Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study n=2532 Participants Participants in the parent study who received placebo subcutaneous injections either Q2W or QM, and received evolocumab 140 mg every 2 weeks Q2W or 420 mg monthly QM in the open label extension, according to the participant's preference.	Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study n=2499 Participants Participants in the parent study who received evolocumab subcutaneous injections either Q2W or QM, and received evolocumab 140 mg Q2W or 420 mg QM in the open label extension according to the participant's preference.
Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit Week 12	-55.93 Percent Change Standard Deviation 33.73	-58.43 Percent Change Standard Deviation 30.64
Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit Week 24	-56.69 Percent Change Standard Deviation 33.58	-58.38 Percent Change Standard Deviation 31.52
Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit Week 48	-58.52 Percent Change Standard Deviation 33.66	-59.05 Percent Change Standard Deviation 33.06
Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit Week 72	-56.35 Percent Change Standard Deviation 33.73	-56.90 Percent Change Standard Deviation 33.14
Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit Week 96	-55.70 Percent Change Standard Deviation 33.72	-56.62 Percent Change Standard Deviation 33.36
Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit Week 120	-53.37 Percent Change Standard Deviation 36.77	-54.89 Percent Change Standard Deviation 35.99
Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit Week 144	-56.96 Percent Change Standard Deviation 32.82	-57.38 Percent Change Standard Deviation 32.34
Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit Week 168	-56.49 Percent Change Standard Deviation 37.04	-58.22 Percent Change Standard Deviation 34.60
Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit Week 192	-57.42 Percent Change Standard Deviation 35.43	-58.81 Percent Change Standard Deviation 33.27
Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit Week 216	-54.68 Percent Change Standard Deviation 35.53	-57.11 Percent Change Standard Deviation 32.89
Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit Week 260	-53.69 Percent Change Standard Deviation 37.51	-56.63 Percent Change Standard Deviation 36.14

SECONDARY outcome

Timeframe: Week 12, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 168, Week 192, Week 216, Week 260

Population: OLE Safety Analysis Set which included all participants who received at least 1 dose of open-label evolocumab in the OLE study.

Outcome measures

Measure	Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study n=2532 Participants Participants in the parent study who received placebo subcutaneous injections either Q2W or QM, and received evolocumab 140 mg every 2 weeks Q2W or 420 mg monthly QM in the open label extension, according to the participant's preference.	Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study n=2499 Participants Participants in the parent study who received evolocumab subcutaneous injections either Q2W or QM, and received evolocumab 140 mg Q2W or 420 mg QM in the open label extension according to the participant's preference.
Percentage of Participants Who Achieved an LDL-C Level < 40 mg/dL Week 48	61.7 Percentage of Participants Interval 59.8 to 63.7	61.9 Percentage of Participants Interval 60.0 to 63.9
Percentage of Participants Who Achieved an LDL-C Level < 40 mg/dL Week 72	59.7 Percentage of Participants Interval 57.7 to 61.7	58.5 Percentage of Participants Interval 56.5 to 60.5
Percentage of Participants Who Achieved an LDL-C Level < 40 mg/dL Week 12	58.7 Percentage of Participants Interval 56.7 to 60.6	61.4 Percentage of Participants Interval 59.4 to 63.3
Percentage of Participants Who Achieved an LDL-C Level < 40 mg/dL Week 24	60.2 Percentage of Participants Interval 58.2 to 62.1	61.6 Percentage of Participants Interval 59.7 to 63.5
Percentage of Participants Who Achieved an LDL-C Level < 40 mg/dL Week 96	57.3 Percentage of Participants Interval 55.3 to 59.3	59.9 Percentage of Participants Interval 57.8 to 61.9
Percentage of Participants Who Achieved an LDL-C Level < 40 mg/dL Week 120	54.6 Percentage of Participants Interval 52.5 to 56.6	56.4 Percentage of Participants Interval 54.4 to 58.5
Percentage of Participants Who Achieved an LDL-C Level < 40 mg/dL Week 144	59.6 Percentage of Participants Interval 57.6 to 61.7	60.4 Percentage of Participants Interval 58.3 to 62.4
Percentage of Participants Who Achieved an LDL-C Level < 40 mg/dL Week 168	60.9 Percentage of Participants Interval 58.8 to 63.0	61.5 Percentage of Participants Interval 59.4 to 63.5
Percentage of Participants Who Achieved an LDL-C Level < 40 mg/dL Week 192	61.8 Percentage of Participants Interval 59.4 to 64.1	62.3 Percentage of Participants Interval 59.9 to 64.7
Percentage of Participants Who Achieved an LDL-C Level < 40 mg/dL Week 216	56.0 Percentage of Participants Interval 53.6 to 58.3	59.2 Percentage of Participants Interval 56.9 to 61.5
Percentage of Participants Who Achieved an LDL-C Level < 40 mg/dL Week 260	56.9 Percentage of Participants Interval 54.6 to 59.1	59.2 Percentage of Participants Interval 56.9 to 61.4

Adverse Events

Placebo in Parent Study

Serious events: 1077 serious events

Other events: 956 other events

Deaths: 309 deaths

Evolocumab in Parent Study

Serious events: 1045 serious events

Other events: 959 other events

Deaths: 287 deaths

Serious adverse events

Measure	Placebo in Parent Study n=2532 participants at risk Participants with Placebo in Parent Study	Evolocumab in Parent Study n=2499 participants at risk Participants with Evolocumab in Parent Study
Infections and infestations Parotid abscess	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Perihepatic abscess	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Blood and lymphatic system disorders Agranulocytosis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Blood and lymphatic system disorders Anaemia	0.51% 13/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.72% 18/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Blood and lymphatic system disorders Anaemia macrocytic	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Blood and lymphatic system disorders Anaemia of malignant disease	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Blood and lymphatic system disorders Anaemia vitamin B12 deficiency	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Blood and lymphatic system disorders Blood loss anaemia	0.20% 5/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.32% 8/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Blood and lymphatic system disorders Heparin-induced thrombocytopenia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Blood and lymphatic system disorders Iron deficiency anaemia	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Blood and lymphatic system disorders Lymphadenopathy	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Blood and lymphatic system disorders Microcytic anaemia	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Blood and lymphatic system disorders Pancytopenia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Blood and lymphatic system disorders Polycythaemia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Blood and lymphatic system disorders Splenic haemorrhage	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Acute cardiac event	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Acute coronary syndrome	0.39% 10/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.24% 6/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Acute left ventricular failure	0.20% 5/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Acute myocardial infarction	2.9% 74/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	2.1% 52/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Angina pectoris	2.2% 56/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	2.1% 52/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Angina unstable	1.9% 49/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	1.5% 37/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Aortic valve disease	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Aortic valve disease mixed	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Aortic valve stenosis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Arrhythmia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Arrhythmic storm	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Arteriosclerosis coronary artery	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Atrial fibrillation	2.3% 57/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	1.9% 47/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Atrial flutter	0.43% 11/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.52% 13/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Atrial tachycardia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Atrioventricular block	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Atrioventricular block complete	0.36% 9/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.36% 9/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Atrioventricular block second degree	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.20% 5/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Bradycardia	0.32% 8/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.36% 9/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Bundle branch block left	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Cardiac arrest	0.63% 16/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.52% 13/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Cardiac asthma	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Cardiac disorder	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Cardiac failure	1.8% 46/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	1.8% 44/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Cardiac failure acute	0.83% 21/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.68% 17/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Cardiac failure chronic	0.51% 13/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.92% 23/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Cardiac failure congestive	1.5% 37/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	1.6% 40/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Cardio-respiratory arrest	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Cardiogenic shock	0.20% 5/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Cardiomyopathy	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Cardiopulmonary failure	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Cardiovascular disorder	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Cardiovascular insufficiency	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Chronic left ventricular failure	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Congestive cardiomyopathy	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Coronary artery disease	1.6% 41/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	1.2% 30/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Coronary artery insufficiency	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Coronary artery occlusion	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.20% 5/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Coronary artery stenosis	0.32% 8/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.16% 4/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Heart valve incompetence	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Intracardiac thrombus	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Ischaemic cardiomyopathy	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.20% 5/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Left ventricular failure	0.32% 8/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.16% 4/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Mitral valve incompetence	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Mitral valve prolapse	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Mitral valve stenosis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Myocardial infarction	0.99% 25/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.80% 20/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Myocardial ischaemia	0.59% 15/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.44% 11/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Nodal arrhythmia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Palpitations	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Paroxysmal atrioventricular block	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Pericardial effusion	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Pericarditis	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Right ventricular failure	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Sinus arrhythmia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Sinus bradycardia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Sinus node dysfunction	0.28% 7/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.32% 8/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Supraventricular extrasystoles	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Supraventricular tachyarrhythmia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Supraventricular tachycardia	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.32% 8/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Tachyarrhythmia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Tachycardia	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Tricuspid valve incompetence	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Ventricular arrhythmia	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.24% 6/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Ventricular extrasystoles	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Ventricular fibrillation	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Ventricular tachyarrhythmia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Ventricular tachycardia	0.67% 17/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.56% 14/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Cardiac disorders Wolff-Parkinson-White syndrome	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Congenital, familial and genetic disorders Gastrointestinal arteriovenous malformation	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Congenital, familial and genetic disorders Hydrocele	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Congenital, familial and genetic disorders Talipes	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Ear and labyrinth disorders Acute vestibular syndrome	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Ear and labyrinth disorders Deafness	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Ear and labyrinth disorders Deafness neurosensory	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Ear and labyrinth disorders External ear disorder	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Ear and labyrinth disorders Hypoacusis	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Ear and labyrinth disorders Neurosensory hypoacusis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Ear and labyrinth disorders Tinnitus	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Ear and labyrinth disorders Vertigo	0.20% 5/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.16% 4/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Ear and labyrinth disorders Vertigo labyrinthine	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Ear and labyrinth disorders Vertigo positional	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Ear and labyrinth disorders Vestibular ataxia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Endocrine disorders Goitre	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Endocrine disorders Hyperparathyroidism primary	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Endocrine disorders Inappropriate antidiuretic hormone secretion	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Eye disorders Amaurosis fugax	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Eye disorders Cataract	0.43% 11/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.32% 8/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Eye disorders Choroidal detachment	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Eye disorders Conjunctival haemorrhage	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Eye disorders Diabetic retinopathy	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Eye disorders Diplopia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Eye disorders Epiretinal membrane	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Eye disorders Eyelid bleeding	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Eye disorders Eyelid ptosis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Eye disorders Glaucoma	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Eye disorders Macular rupture	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Eye disorders Retinal detachment	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Eye disorders Vision blurred	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Eye disorders Visual impairment	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Abdominal adhesions	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Abdominal hernia	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Abdominal incarcerated hernia	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Abdominal mass	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Abdominal pain	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Abdominal symptom	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Abdominal wall haematoma	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Abnormal faeces	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Anal fissure	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Anal fistula	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Anal stenosis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Barrett's oesophagus	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Colitis	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.20% 5/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Colitis ischaemic	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Colitis ulcerative	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Colon dysplasia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Crohn's disease	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Diarrhoea	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Diverticular perforation	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Diverticulum	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Diverticulum intestinal	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Diverticulum intestinal haemorrhagic	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Duodenal ulcer	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Duodenal ulcer haemorrhage	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Dyspepsia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Dysphagia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Erosive duodenitis	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Faecaloma	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Femoral hernia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Femoral hernia strangulated	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Food poisoning	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Gastric perforation	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Gastric polyps	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Gastric ulcer	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Gastric ulcer haemorrhage	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Gastric ulcer perforation	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Gastric volvulus	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Gastritis	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Gastritis alcoholic	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Gastritis erosive	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Gastritis haemorrhagic	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Gastrointestinal angiodysplasia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Gastrointestinal disorder	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.43% 11/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.64% 16/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Gastrointestinal vascular malformation haemorrhagic	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.24% 6/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Haemorrhagic erosive gastritis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Haemorrhoidal haemorrhage	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Haemorrhoids	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Hiatus hernia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Ileus	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Incarcerated inguinal hernia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Inguinal hernia	0.32% 8/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.44% 11/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Inguinal hernia strangulated	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Intestinal angina	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Intestinal ischaemia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Intestinal perforation	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Intestinal pseudo-obstruction	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Irritable bowel syndrome	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Large intestinal haemorrhage	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Large intestinal obstruction	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Large intestine perforation	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Large intestine polyp	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.24% 6/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Lower gastrointestinal haemorrhage	0.28% 7/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Melaena	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Mesenteric artery thrombosis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Nausea	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Obstructive pancreatitis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Odynophagia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Oedematous pancreatitis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Oesophageal food impaction	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Oesophageal haemorrhage	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Oesophageal stenosis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Oesophageal ulcer	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Oesophageal ulcer haemorrhage	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Oesophageal varices haemorrhage	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Oesophagitis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Pancreatic failure	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Pancreatitis	0.20% 5/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Pancreatitis acute	0.20% 5/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.40% 10/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Pancreatitis chronic	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Pancreatitis necrotising	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Peptic ulcer	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Peptic ulcer haemorrhage	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Proctitis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Rectal haemorrhage	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.16% 4/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Rectal prolapse	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Retroperitoneal haemorrhage	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Salivary gland cyst	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Small intestinal haemorrhage	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Small intestinal obstruction	0.24% 6/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.16% 4/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Subileus	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Umbilical hernia	0.24% 6/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Upper gastrointestinal haemorrhage	0.20% 5/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.32% 8/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Varices oesophageal	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Gastrointestinal disorders Vomiting	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
General disorders Adverse drug reaction	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
General disorders Asthenia	0.20% 5/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
General disorders Chest discomfort	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
General disorders Chest pain	0.59% 15/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.28% 7/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
General disorders Complication associated with device	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
General disorders Death	0.36% 9/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.40% 10/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
General disorders Exercise tolerance decreased	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
General disorders Hernia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
General disorders Impaired healing	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
General disorders Implant site haematoma	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
General disorders Implant site pain	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
General disorders Inflammation	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
General disorders Multiple organ dysfunction syndrome	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.24% 6/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
General disorders Non-cardiac chest pain	1.0% 26/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	1.5% 37/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
General disorders Pneumatosis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
General disorders Prosthetic cardiac valve stenosis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
General disorders Pyrexia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
General disorders Stent-graft endoleak	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
General disorders Sudden cardiac death	0.28% 7/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
General disorders Sudden death	0.39% 10/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.24% 6/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
General disorders Systemic inflammatory response syndrome	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
General disorders Vascular stent occlusion	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
General disorders Vascular stent stenosis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Hepatobiliary disorders Alcoholic liver disease	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Hepatobiliary disorders Bile duct stone	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Hepatobiliary disorders Biliary dilatation	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Hepatobiliary disorders Biliary tract disorder	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Hepatobiliary disorders Cholangitis acute	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Hepatobiliary disorders Cholecystitis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.16% 4/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Hepatobiliary disorders Cholecystitis acute	0.28% 7/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.40% 10/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Hepatobiliary disorders Cholecystitis chronic	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Hepatobiliary disorders Cholelithiasis	0.51% 13/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.44% 11/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Hepatobiliary disorders Chronic hepatic failure	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Hepatobiliary disorders Cirrhosis alcoholic	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Hepatobiliary disorders Hepatic cirrhosis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Hepatobiliary disorders Hepatic steatosis	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Hepatobiliary disorders Hepatitis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Hepatobiliary disorders Hyperplastic cholecystopathy	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Hepatobiliary disorders Jaundice cholestatic	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Hepatobiliary disorders Liver injury	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Immune system disorders Anaphylactic reaction	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Immune system disorders Contrast media allergy	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Abdominal abscess	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Abscess	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Abscess bacterial	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Abscess limb	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Acute endocarditis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Anal abscess	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Appendicitis	0.28% 7/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Appendicitis perforated	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Arthritis bacterial	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Arthritis infective	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Asymptomatic COVID-19	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Atypical pneumonia	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Bacteraemia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Bacterial infection	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Breast abscess	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Bronchitis	0.32% 8/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.40% 10/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations COVID-19	0.59% 15/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.60% 15/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations COVID-19 pneumonia	1.3% 32/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.92% 23/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Cellulitis	0.67% 17/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.80% 20/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Cholecystitis infective	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Cholera	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Clostridium difficile colitis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Clostridium difficile infection	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Coccidioidomycosis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Colonic abscess	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Coronavirus infection	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Cystitis	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Cystitis klebsiella	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Device related infection	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Diabetic foot infection	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Diabetic gangrene	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Diverticulitis	0.43% 11/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.28% 7/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Diverticulitis intestinal haemorrhagic	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Eczema infected	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Endocarditis bacterial	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Enterocolitis bacterial	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Epididymitis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Erysipelas	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Escherichia bacteraemia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Escherichia sepsis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Escherichia urinary tract infection	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Extradural abscess	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Fungal skin infection	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Gallbladder abscess	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Gallbladder empyema	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Gangrene	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.20% 5/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Gastroenteritis	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Gastroenteritis bacterial	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Gastroenteritis viral	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Groin abscess	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Herpes zoster	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Infected skin ulcer	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Infection	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Infectious pleural effusion	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Influenza	0.43% 11/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.24% 6/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Intervertebral discitis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Joint abscess	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Kidney infection	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Klebsiella infection	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Klebsiella sepsis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Localised infection	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Lung abscess	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Lyme disease	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Meningoencephalitis viral	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Metapneumovirus infection	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Neutropenic sepsis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Orchitis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Osteomyelitis	0.24% 6/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Osteomyelitis acute	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Osteomyelitis chronic	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Otitis media chronic	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Paronychia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Perineal abscess	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Peritonitis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Pharyngeal abscess	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Pneumonia	2.0% 50/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	3.0% 74/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Pneumonia aspiration	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.20% 5/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Pneumonia bacterial	0.36% 9/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Pneumonia escherichia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Pneumonia legionella	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Pneumonia pseudomonal	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Pneumonia streptococcal	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Pneumonia viral	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Post procedural infection	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Post procedural sepsis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Postoperative wound infection	0.20% 5/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Pulmonary tuberculosis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Pyelonephritis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Pyelonephritis acute	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Rectal abscess	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Respiratory tract infection	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Rocky mountain spotted fever	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Sepsis	0.55% 14/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.92% 23/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Septic arthritis staphylococcal	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Septic shock	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Serratia infection	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Staphylococcal abscess	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Staphylococcal bacteraemia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Staphylococcal infection	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Staphylococcal osteomyelitis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Staphylococcal sepsis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Streptococcal bacteraemia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Streptococcal sepsis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Subcutaneous abscess	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Tracheobronchitis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Tuberculosis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Upper respiratory tract infection	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Urinary tract infection	0.55% 14/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.52% 13/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Urinary tract infection bacterial	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Urinary tract infection pseudomonal	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Urosepsis	0.28% 7/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.16% 4/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Vestibular neuronitis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Viral upper respiratory tract infection	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Wound infection	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Wound infection bacterial	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Wound sepsis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Accidental overdose	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Anaemia postoperative	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Ankle fracture	0.20% 5/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Aortic pseudoaneurysm	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Arterial injury	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Arthropod bite	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Brain contusion	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Burns second degree	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Burns third degree	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Carbon monoxide poisoning	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Cardiac procedure complication	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Cartilage injury	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Cervical vertebral fracture	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Compression fracture	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Concussion	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Contusion	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Coronary artery reocclusion	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Coronary artery restenosis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Craniocerebral injury	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Crush injury	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Dislocation of sternum	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Dural tear	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Face injury	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Fall	0.36% 9/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.40% 10/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Femoral neck fracture	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Femoral nerve injury	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Femur fracture	0.24% 6/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Foot fracture	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Forearm fracture	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Foreign body in gastrointestinal tract	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Fracture	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Fractured sacrum	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Frostbite	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Graft haemorrhage	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Gun shot wound	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Head injury	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Hip fracture	0.20% 5/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.36% 9/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Humerus fracture	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.20% 5/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Ilium fracture	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Incarcerated incisional hernia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Incisional hernia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Intentional overdose	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Intervertebral disc injury	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Jaw fracture	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Joint dislocation	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Ligament rupture	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Ligament sprain	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Limb crushing injury	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Limb injury	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Lower limb fracture	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Lumbar vertebral fracture	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Meniscus injury	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Multiple injuries	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Overdose	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Patella fracture	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Pelvic fracture	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Pelvic organ injury	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Periprocedural myocardial infarction	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Pneumothorax traumatic	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Post procedural complication	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Post procedural haematoma	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Post procedural haemorrhage	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Post procedural hypotension	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Post procedural pulmonary embolism	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Postoperative respiratory failure	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Postoperative wound complication	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Procedural pain	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Procedural pneumothorax	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Radiation proctitis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Rib fracture	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.24% 6/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Road traffic accident	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.16% 4/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Skin laceration	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Spinal compression fracture	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Spinal fracture	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Splenic rupture	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Subdural haematoma	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.20% 5/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Tendon injury	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Tendon rupture	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Thermal burn	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Thoracic vertebral fracture	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Tibia fracture	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Upper limb fracture	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Vascular access complication	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Vascular graft complication	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Vascular graft occlusion	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Vascular pseudoaneurysm	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Vascular pseudoaneurysm ruptured	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Wound	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Wound complication	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Wound dehiscence	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Injury, poisoning and procedural complications Wound necrosis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Investigations Anticoagulation drug level above therapeutic	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Investigations Anticoagulation drug level below therapeutic	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Investigations Blood creatinine increased	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Investigations Hepatic enzyme increased	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Investigations International normalised ratio decreased	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Investigations International normalised ratio increased	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Investigations Respiratory syncytial virus test positive	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Investigations Squamous cell carcinoma antigen	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Investigations Transaminases increased	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Investigations Troponin I increased	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Investigations Troponin increased	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Metabolism and nutrition disorders Decreased appetite	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Metabolism and nutrition disorders Dehydration	0.24% 6/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.40% 10/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Metabolism and nutrition disorders Diabetes mellitus	0.32% 8/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.48% 12/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Metabolism and nutrition disorders Diabetes mellitus inadequate control	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.16% 4/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Metabolism and nutrition disorders Diabetic ketoacidosis	0.20% 5/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Metabolism and nutrition disorders Failure to thrive	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Metabolism and nutrition disorders Gout	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Metabolism and nutrition disorders Hypercalcaemia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Metabolism and nutrition disorders Hyperglycaemia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Metabolism and nutrition disorders Hyperglycaemic hyperosmolar nonketotic syndrome	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Metabolism and nutrition disorders Hyperkalaemia	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Metabolism and nutrition disorders Hypertriglyceridaemia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Metabolism and nutrition disorders Hypervolaemia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Metabolism and nutrition disorders Hypoglycaemia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Metabolism and nutrition disorders Hypokalaemia	0.20% 5/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Metabolism and nutrition disorders Hyponatraemia	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.20% 5/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Metabolism and nutrition disorders Hypovolaemia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Metabolism and nutrition disorders Lactic acidosis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Metabolism and nutrition disorders Malnutrition	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Metabolism and nutrition disorders Mineral deficiency	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Metabolism and nutrition disorders Obesity	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Metabolism and nutrition disorders Type 2 diabetes mellitus	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Arthralgia	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Arthritis	0.24% 6/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Arthropathy	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Back disorder	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Back pain	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.32% 8/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Bursitis	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Cervical spinal stenosis	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Chondromalacia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Chondropathy	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Compartment syndrome	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Exostosis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Gouty arthritis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Haematoma muscle	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Intervertebral disc degeneration	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Intervertebral disc disorder	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Intervertebral disc displacement	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Intervertebral disc protrusion	0.32% 8/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.24% 6/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Joint swelling	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Knee impingement syndrome	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Kyphosis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Lumbar spinal stenosis	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.36% 9/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Muscular weakness	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.24% 6/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.24% 6/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Myalgia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Myopathy	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Osteoarthritis	1.5% 37/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	1.4% 36/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Osteolysis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Osteonecrosis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Pain in jaw	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Pathological fracture	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Polyarthritis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Polymyalgia rheumatica	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Psoriatic arthropathy	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Rhabdomyolysis	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Rheumatoid arthritis	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Rotator cuff syndrome	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Scoliosis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Spinal disorder	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Spinal osteoarthritis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.32% 8/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Spinal pain	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Spinal stenosis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.20% 5/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Spondylitis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Spondyloarthropathy	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Spondylolisthesis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Synovial cyst	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Vertebral foraminal stenosis	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Acute myeloid leukaemia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma gastric	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma of colon	0.20% 5/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.40% 10/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma pancreas	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Anal cancer metastatic	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Anal squamous cell carcinoma	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) B-cell lymphoma	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Benign male reproductive tract neoplasm	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Benign neoplasm of ampulla of Vater	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Benign pancreatic neoplasm	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Benign spleen tumour	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder adenocarcinoma stage unspecified	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder cancer	0.24% 6/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.20% 5/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder cancer recurrent	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder cancer stage I, with cancer in situ	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder cancer stage I, without cancer in situ	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder neoplasm	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder papilloma	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder transitional cell carcinoma	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.20% 5/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder transitional cell carcinoma metastatic	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Brain cancer metastatic	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer female	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer metastatic	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer stage I	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bronchial carcinoma	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Carcinoid tumour pulmonary	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Cholangiocarcinoma	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Chronic lymphocytic leukaemia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Chronic myeloid leukaemia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Clear cell renal cell carcinoma	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon adenoma	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon cancer	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colorectal adenocarcinoma	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colorectal cancer	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Diffuse large B-cell lymphoma	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Diffuse large B-cell lymphoma stage IV	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Ductal adenocarcinoma of pancreas	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Endometrial adenocarcinoma	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Endometrial cancer	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Follicular lymphoma	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Gallbladder cancer metastatic	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Gastric cancer	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Gastrointestinal cancer metastatic	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Gastrointestinal tract adenoma	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Glioblastoma multiforme	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Glottis carcinoma	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Hepatic cancer	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Hepatocellular carcinoma	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Intraductal proliferative breast lesion	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Invasive breast carcinoma	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Invasive ductal breast carcinoma	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Invasive lobular breast carcinoma	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Keratoacanthoma	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Laryngeal cancer	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Laryngeal cancer stage III	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Laryngeal papilloma	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Laryngeal squamous cell carcinoma	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Leiomyoma	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lip and/or oral cavity cancer	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung adenocarcinoma	0.39% 10/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.24% 6/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung adenocarcinoma stage I	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung adenocarcinoma stage IV	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung cancer metastatic	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung carcinoma cell type unspecified stage I	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung neoplasm	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung neoplasm malignant	0.20% 5/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.24% 6/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lymphoma	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant melanoma	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant pleural effusion	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Mantle cell lymphoma stage III	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Meningioma benign	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to bone	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to central nervous system	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to liver	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to lung	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to spinal cord	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to spine	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastatic neoplasm	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastatic squamous cell carcinoma	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Myelodysplastic syndrome	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Nasopharyngeal cancer	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasm malignant	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neuroendocrine carcinoma of the skin	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neuroendocrine tumour	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Nodular melanoma	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Non-small cell lung cancer	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Non-small cell lung cancer metastatic	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Non-small cell lung cancer stage IV	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Oesophageal adenocarcinoma stage III	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Spondylitic myelopathy	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Oesophageal cancer metastatic	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Oesophageal carcinoma	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Ovarian cancer	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Ovarian cancer stage II	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Paget's disease of nipple	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic carcinoma	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.20% 5/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic carcinoma metastatic	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Subarachnoid haemorrhage	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.16% 4/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic carcinoma stage IV	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic neoplasm	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Papillary cystadenoma lymphomatosum	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pelvic neoplasm	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Penile cancer	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Phosphaturic mesenchymal tumour	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pituitary tumour benign	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Plasma cell myeloma	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pleomorphic adenoma	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Porocarcinoma	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostate cancer	0.71% 18/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.64% 16/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostate cancer metastatic	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostate cancer stage I	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostate cancer stage IV	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostatic adenoma	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Rectal adenocarcinoma	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Rectal cancer	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Rectal cancer metastatic	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Renal adenoma	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Renal cancer	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Syncope	0.75% 19/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.56% 14/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Renal cancer stage II	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Renal cancer stage IV	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Renal cell carcinoma	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Renal cell carcinoma stage I	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Renal neoplasm	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Skin cancer	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Small cell carcinoma	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Small cell lung cancer	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.16% 4/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Small cell lung cancer extensive stage	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Small cell lung cancer metastatic	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Soft tissue sarcoma	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma of lung	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma of skin	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma of the hypopharynx	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma of the tongue	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Testis cancer	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Thyroid cancer	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Thyroid neoplasm	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tonsil cancer	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Transitional cell carcinoma	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Transitional cell carcinoma urethra	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Uterine cancer	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Uterine leiomyoma	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Vulval cancer stage III	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Aphasia	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Autonomic nervous system imbalance	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Axonal neuropathy	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Balance disorder	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Basilar artery stenosis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Carotid arteriosclerosis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Carotid artery disease	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Carotid artery occlusion	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Carotid artery stenosis	0.43% 11/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.40% 10/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Carpal tunnel syndrome	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Cauda equina syndrome	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Cerebral amyloid angiopathy	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Cerebral arteriosclerosis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Cerebral ataxia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Cerebral haemorrhage	0.20% 5/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Cerebral infarction	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Cerebral ischaemia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Cerebrovascular accident	0.99% 25/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.80% 20/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Cervical radiculopathy	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Cognitive disorder	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Dementia	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Dementia Alzheimer's type	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Dizziness	0.32% 8/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Dizziness postural	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Embolic stroke	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Encephalopathy	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Thalamic infarction	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Epilepsy	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Facial paralysis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Facial paresis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Focal dyscognitive seizures	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Generalised tonic-clonic seizure	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Guillain-Barre syndrome	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Haemorrhage intracranial	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Haemorrhagic cerebral infarction	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Haemorrhagic stroke	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Headache	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Hemianopia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Hemiparaesthesia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Hemiparesis	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Hepatic encephalopathy	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Hypertensive encephalopathy	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Hypoaesthesia	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Hypoxic-ischaemic encephalopathy	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Intracranial aneurysm	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Ischaemic cerebral infarction	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Ischaemic stroke	0.71% 18/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	1.1% 27/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Lacunar infarction	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Lacunar stroke	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Loss of consciousness	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Lumbar radiculopathy	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Memory impairment	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Metabolic encephalopathy	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Migraine	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Monoparesis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Moyamoya disease	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Myelopathy	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Nerve compression	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Paraesthesia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Paresis cranial nerve	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Parkinson's disease	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Partial seizures	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Peripheral nerve lesion	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Peripheral sensorimotor neuropathy	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Peripheral sensory neuropathy	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Phantom limb syndrome	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Polyneuropathy	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Post stroke epilepsy	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Presyncope	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Psychogenic seizure	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Radiculopathy	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Sciatica	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Seizure	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Spinal cord compression	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Toxic encephalopathy	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Transient global amnesia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Transient ischaemic attack	0.43% 11/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.56% 14/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Vascular dementia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Vascular encephalopathy	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Vertebrobasilar insufficiency	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Vertebrobasilar stroke	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Nervous system disorders Vocal cord paralysis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Product Issues Device dislocation	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Product Issues Device failure	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Product Issues Device loosening	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Product Issues Device malfunction	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Product Issues Device mechanical issue	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Product Issues Device occlusion	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Product Issues Device power source issue	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Product Issues Device stimulation issue	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Product Issues Lead dislodgement	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Psychiatric disorders Acute psychosis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Psychiatric disorders Alcohol abuse	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.16% 4/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Psychiatric disorders Alcohol withdrawal syndrome	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Psychiatric disorders Anxiety	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Psychiatric disorders Anxiety disorder due to a general medical condition	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Psychiatric disorders Completed suicide	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Psychiatric disorders Confusional state	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Psychiatric disorders Delirium	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Psychiatric disorders Depression	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Psychiatric disorders Major depression	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Psychiatric disorders Mania	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Psychiatric disorders Mental status changes	0.36% 9/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Psychiatric disorders Paranoia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Psychiatric disorders Post-traumatic stress disorder	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Psychiatric disorders Stress	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Psychiatric disorders Suicidal ideation	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Acute kidney injury	0.99% 25/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	1.2% 30/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Bladder stenosis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Calculus bladder	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Calculus urinary	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Chronic kidney disease	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.24% 6/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Cystitis haemorrhagic	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders End stage renal disease	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.16% 4/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Focal segmental glomerulosclerosis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Glomerulonephritis membranous	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Haematuria	0.20% 5/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Haemorrhage urinary tract	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Hydronephrosis	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Incontinence	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Nephrolithiasis	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.36% 9/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Nephropathy toxic	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Nephrotic syndrome	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Obstructive nephropathy	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Renal artery stenosis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Renal colic	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Renal cyst	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Renal embolism	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Renal failure	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Renal haematoma	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Renal haemorrhage	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Renal impairment	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Renal mass	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Ureteric obstruction	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Ureteric stenosis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Ureterolithiasis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.20% 5/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Urethral perforation	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Urethral stenosis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Urinary retention	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Urinary tract disorder	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Renal and urinary disorders Urinary tract obstruction	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Reproductive system and breast disorders Adnexa uteri mass	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Reproductive system and breast disorders Balanoposthitis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Reproductive system and breast disorders Benign prostatic hyperplasia	0.36% 9/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.28% 7/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Reproductive system and breast disorders Breast cyst	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Reproductive system and breast disorders Endometrial hyperplasia	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Reproductive system and breast disorders Erectile dysfunction	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Reproductive system and breast disorders Genital haemorrhage	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Reproductive system and breast disorders Ovarian cyst	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Reproductive system and breast disorders Pelvic haematoma	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Reproductive system and breast disorders Pelvic organ prolapse	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Reproductive system and breast disorders Prostatic dysplasia	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Reproductive system and breast disorders Prostatitis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Reproductive system and breast disorders Prostatomegaly	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Reproductive system and breast disorders Uterine inflammation	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Reproductive system and breast disorders Uterine polyp	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Reproductive system and breast disorders Uterine prolapse	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Reproductive system and breast disorders Vaginal prolapse	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Acute pulmonary oedema	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Acute respiratory distress syndrome	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	0.32% 8/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.92% 23/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Aspiration	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Asthma	0.28% 7/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.16% 4/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Asthma late onset	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Bronchitis chronic	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Bronchopulmonary disease	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Bronchospasm	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.99% 25/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	1.2% 30/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Chronic respiratory failure	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.24% 6/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.36% 9/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Epiglottic mass	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Hydrothorax	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Idiopathic pulmonary fibrosis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Interstitial lung disease	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.20% 5/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Lung disorder	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Lung infiltration	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Pneumonitis aspiration	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Pneumothorax spontaneous	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.47% 12/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.48% 12/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Pulmonary fibrosis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Pulmonary haemorrhage	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Pulmonary hypertension	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Pulmonary oedema	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Respiratory arrest	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Respiratory distress	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.51% 13/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.64% 16/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Sleep apnoea syndrome	0.20% 5/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Respiratory, thoracic and mediastinal disorders Tracheal stenosis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Skin and subcutaneous tissue disorders Actinic keratosis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Skin and subcutaneous tissue disorders Angioedema	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Skin and subcutaneous tissue disorders Blister	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Skin and subcutaneous tissue disorders Cutaneous lupus erythematosus	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Skin and subcutaneous tissue disorders Dermal cyst	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Skin and subcutaneous tissue disorders Dermatitis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Skin and subcutaneous tissue disorders Dermatitis bullous	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Skin and subcutaneous tissue disorders Dermatitis herpetiformis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Skin and subcutaneous tissue disorders Diabetic foot	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.16% 4/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Skin and subcutaneous tissue disorders Erythema multiforme	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Skin and subcutaneous tissue disorders Hyperkeratosis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Skin and subcutaneous tissue disorders Ischaemic skin ulcer	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Skin and subcutaneous tissue disorders Neuropathic ulcer	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Skin and subcutaneous tissue disorders Psoriasis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Skin and subcutaneous tissue disorders Skin lesion	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Skin and subcutaneous tissue disorders Skin ulcer	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Surgical and medical procedures Hip arthroplasty	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Surgical and medical procedures Skin neoplasm excision	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Surgical and medical procedures Tissue expansion procedure	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Accelerated hypertension	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Aneurysm	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Aortic aneurysm	0.51% 13/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.40% 10/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Aortic aneurysm rupture	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Aortic arteriosclerosis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Aortic dissection	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Aortic stenosis	0.28% 7/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.40% 10/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Aortic thrombosis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Arterial perforation	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Arterial stenosis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Arteriosclerosis	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.28% 7/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Arteriovenous fistula	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Bleeding varicose vein	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Blue toe syndrome	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Circulatory collapse	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Deep vein thrombosis	0.28% 7/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.16% 4/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Diabetic macroangiopathy	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Diabetic vascular disorder	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Dry gangrene	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.20% 5/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Embolism arterial	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Extremity necrosis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Femoral artery aneurysm	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Giant cell arteritis	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Haematoma	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Hypertension	0.79% 20/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.40% 10/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Hypertensive crisis	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.16% 4/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Hypertensive emergency	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Hypertensive urgency	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Hypotension	0.28% 7/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.20% 5/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Hypovolaemic shock	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Iliac artery embolism	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Iliac artery stenosis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Intermittent claudication	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Internal haemorrhage	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Leriche syndrome	0.12% 3/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Lymphoedema	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Orthostatic hypotension	0.20% 5/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.20% 5/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Peripheral arterial occlusive disease	0.95% 24/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	1.0% 26/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Peripheral artery aneurysm	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Peripheral artery occlusion	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Peripheral artery stenosis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.12% 3/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Peripheral artery thrombosis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Peripheral circulatory failure	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Peripheral embolism	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Peripheral ischaemia	0.24% 6/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.40% 10/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Peripheral vascular disorder	0.16% 4/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.40% 10/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Peripheral venous disease	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Raynaud's phenomenon	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Shock	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Shock haemorrhagic	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Subclavian artery embolism	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Subclavian artery occlusion	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.04% 1/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Subclavian vein occlusion	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Superior vena cava stenosis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Thrombophlebitis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Thrombosis	0.08% 2/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.16% 4/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Varicose vein	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Vena cava thrombosis	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Venous haemorrhage	0.04% 1/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.00% 0/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Venous thrombosis limb	0.00% 0/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	0.08% 2/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.

Other adverse events

Measure	Placebo in Parent Study n=2532 participants at risk Participants with Placebo in Parent Study	Evolocumab in Parent Study n=2499 participants at risk Participants with Evolocumab in Parent Study
Infections and infestations Bronchitis	6.4% 162/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	6.9% 173/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Nasopharyngitis	6.2% 157/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	6.2% 156/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Infections and infestations Upper respiratory tract infection	8.2% 208/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	6.5% 162/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Metabolism and nutrition disorders Diabetes mellitus	5.5% 139/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	5.4% 135/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Arthralgia	5.7% 144/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	5.5% 138/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Musculoskeletal and connective tissue disorders Back pain	5.3% 133/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	5.5% 137/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.
Vascular disorders Hypertension	12.9% 327/2532 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.	14.2% 355/2499 • Day 1 up to approximately 5 years during the OLE study. All-Cause Mortality is reported for all enrolled participants. Serious and Other Adverse Events are reported for the Safety Analysis Set defined as all participants who received at least 1 dose of open-label evolocumab in the OLE study.

Additional Information

Study Director

Amgen Inc.

Phone: 866-572-6436

Email: medinfo@amgen.com

Results disclosure agreements

• Principal investigator is a sponsor employee The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.
• Publication restrictions are in place

Restriction type: OTHER